publication . Article . Other literature type . 2014

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

Thomas Reiner; Wolfgang A. Weber; Christian Brand; Beatriz Salinas; Christopher Irwin; Yasiri Portorreal; Pooja Desai; Yachao Zhang;
Open Access English
  • Published: 01 May 2014 Journal: Neoplasia, issue 5, pages 432-440 (issn: 14765586, Copyright policy)
  • Publisher: Neoplasia Press, Inc. Published by Elsevier Inc.
Abstract
AbstractNew intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression. Importantly, s...
Subjects
free text keywords: Cancer Research, Article, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cell culture, DNA repair, Small molecule, PARP1, In vivo, Imaging agent, Poly ADP ribose polymerase, Neuroimaging, Biology, Pathology, medicine.medical_specialty, medicine
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Bioorthogonal Strategies for Targeted PET Imaging Probe Development
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1K25EB016673-01
  • Funding stream: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
Communities
Neuroinformatics
30 references, page 1 of 2

Rouleau, M, Patel, A, Hendzel, MJ, Kaufmann, SH, Poirier, GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10: 293-301 [OpenAIRE] [PubMed]

Gradwohl, G, Menissier de Muricia, J, Molinete, M, Simonin, F, Koken, M, Hoeumakers, J, de Muricia, G. The second zinc-finger domain of poly(ADP-ribose) polymerase determines the specificity for single-stranded breaks in DNA. Proc Natl Acad Sci U S A. 1990; 87: 2990-2994 [OpenAIRE] [PubMed]

Hassa, PO, Hottiger, MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008; 12: 3046-3082 [OpenAIRE]

Thurber, GM, Yang, KS, Reiner, T, Kohler, RH, Sorger, P, Mitchison, T, Weissleder, R. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun. 2013; 4: 1505-1513 [OpenAIRE] [PubMed]

Reiner, T, Lacy, J, Keliher, EJ, Yang, KS, Ullal, A, Kohler, RH, Vinegoni, C, Weissleder, R. Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents. Neoplasia. 2012; 14: 169-177 [OpenAIRE] [PubMed]

Menear, KA, Adcock, C, Boulter, R, Cockcroft, XL, Copsey, L, Cranston, A, Dillon, KJ, Drzewiecki, J, Garman, S, Gomez, S. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008; 51: 6581-6591 [PubMed]

Thurber, G, Reiner, T, Yang, K, Kohler, R, Weissleder, R. Effect of Small Molecule Modification on Single Cell Pharmacokinetics of PARP Inhibitors. Mol Cancer Ther. 2014; 13: 986-995 [OpenAIRE] [PubMed]

Ossovskaya, V, Koo, IC, Kaldjian, EP, Alvares, C, Sherman, BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer. 2010; 1: 812-821 [OpenAIRE] [PubMed]

Bieche, dM, Linderau, R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res. 1996; 2: 1163-1167 [OpenAIRE] [PubMed]

Rojo, F, Garcia-Parra, J, Zazo, S, Tusquets, I, Ferrer-Lozano, J, Menendez, S, Eroles, P, Chamizo, C, Servitja, S, Ramirez-Merino, N. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012; 23: 1156-1164 [OpenAIRE] [PubMed]

Staibano, S, Pepe, S, Lo Muzio, L, Somma, P, Mascolo, M, Argenziano, G, Scalvenzi, M, Salvatore, G, Fabbrocini, G, Molea, G. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol. 2005; 36: 724-731 [PubMed]

Galia, A, Calogero, AE, Condorelli, R, Fraggetta, F, La Corte, A, Ridolfo, F, Bosco, P, Castiglione, R, Salemi, M. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 2012; 56: 45-48 [OpenAIRE]

Barton, VN, Donson, AM, Kleinschmidt-DeMasters, BK, Gore, L, Liu, AK, Foreman, NK. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer. 2009; 53: 1227-1230 [OpenAIRE] [PubMed]

Wen, YP, Kesari, S, Chattopadhyay, R, Naidu, CV, Izumi, T. Malignant Gliomas in Adults. N Engl J Med. 2008; 359: 492-507 [PubMed]

Kreth, FW, Thon, N, Simon, M, Westphal, M, Schackert, G, Nikkhah, G, Hentschel, B, Reifenberger, G, Pietsch, T, Weller, M. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013; 24: 3117-3123 [OpenAIRE] [PubMed]

30 references, page 1 of 2
Any information missing or wrong?Report an Issue